ATE352288T1 - Verfahren zur herstellung von pharmazeutisch akzeptierbares und steriles beclomethasone dipropionate - Google Patents

Verfahren zur herstellung von pharmazeutisch akzeptierbares und steriles beclomethasone dipropionate

Info

Publication number
ATE352288T1
ATE352288T1 AT99955895T AT99955895T ATE352288T1 AT E352288 T1 ATE352288 T1 AT E352288T1 AT 99955895 T AT99955895 T AT 99955895T AT 99955895 T AT99955895 T AT 99955895T AT E352288 T1 ATE352288 T1 AT E352288T1
Authority
AT
Austria
Prior art keywords
sterile
beclomethasone dipropionate
pharmaceutically acceptable
directed
preparation
Prior art date
Application number
AT99955895T
Other languages
English (en)
Inventor
Eva Bernini
Chiara Malvolti
Raffaella Garzia
Gaetano Brambilla
Paolo Chiesi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE352288T1 publication Critical patent/ATE352288T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT99955895T 1998-11-03 1999-10-28 Verfahren zur herstellung von pharmazeutisch akzeptierbares und steriles beclomethasone dipropionate ATE352288T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002364A IT1303692B1 (it) 1998-11-03 1998-11-03 Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.

Publications (1)

Publication Number Publication Date
ATE352288T1 true ATE352288T1 (de) 2007-02-15

Family

ID=11380994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955895T ATE352288T1 (de) 1998-11-03 1999-10-28 Verfahren zur herstellung von pharmazeutisch akzeptierbares und steriles beclomethasone dipropionate

Country Status (26)

Country Link
US (1) US6464958B1 (de)
EP (2) EP1832279B1 (de)
JP (1) JP2002528484A (de)
KR (1) KR100783096B1 (de)
CN (1) CN1158997C (de)
AT (1) ATE352288T1 (de)
AU (1) AU762367B2 (de)
BR (2) BRPI9915251B8 (de)
CA (2) CA2614633C (de)
CY (2) CY1107659T1 (de)
CZ (2) CZ306939B6 (de)
DE (1) DE69935002T2 (de)
DK (2) DK1832279T3 (de)
EA (1) EA003228B1 (de)
ES (1) ES2281197T3 (de)
HU (2) HU230121B1 (de)
IT (1) IT1303692B1 (de)
NO (1) NO20012175L (de)
NZ (1) NZ511305A (de)
PL (1) PL195908B1 (de)
PT (1) PT1126823E (de)
SI (1) SI1126823T1 (de)
SK (2) SK288316B6 (de)
TR (1) TR200101209T2 (de)
WO (1) WO2000025746A2 (de)
ZA (1) ZA200103526B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
SG98420A1 (en) * 2000-07-13 2003-09-19 Purzer Pharmaceutical Co Ltd Method for transferring one or more active ingredients between different phase carriers
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
EP1476201B1 (de) 2002-02-19 2008-12-24 Resolution Chemicals Limited Auf lösungsmitteln basierende sterilisation von steroiden
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004073685A1 (en) * 2003-02-20 2004-09-02 Constant Research & Development Limited Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor
EP1454636A1 (de) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilisierung von Glucocorticoid-Arzneimittelteilchen zur Anwendung in der Lunge
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0319500D0 (en) * 2003-08-19 2003-09-17 Resolution Chemicals Ltd Particle-size reduction apparatus,and use thereof
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
CA2546454A1 (en) * 2003-11-18 2005-06-02 Yansong Shan Healthy pleasurable inhalation device
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
ATE497787T1 (de) * 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
GB0406515D0 (en) * 2004-03-23 2004-04-28 Novartis Ag Organic compounds
CA2559915C (en) 2004-03-23 2013-07-02 Novartis Ag Micronization of pharmaceutically active agents
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) * 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
EP2623095A1 (de) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injizierbare Olanzapin-Formulierungen in Nanoteilchenform
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
ES2388287T3 (es) 2005-01-20 2012-10-11 Eratech S.R.L. Procedimiento para la preparación de suspensiones concentradas de fármacos y kit correspondiente
EP1968547A1 (de) * 2005-11-29 2008-09-17 Farmabios S.p.A. Verfahren zur herstellung von mikronisierten sterilen steroiden
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
KR20120023663A (ko) * 2009-05-25 2012-03-13 키에시 파르마슈티시 엣스. 피. 에이. 폐 계면활성제 및 스테로이드를 포함하는 치료적 조합
CN103501791B (zh) 2011-05-03 2016-05-18 奇斯药制品公司 用于通过吸入给药的改良皮质类固醇悬浮制剂
DK2704687T3 (en) 2011-05-04 2015-10-05 Chiesi Farma Spa Topical formulation having a corticosteroid as an active ingredient
CN104739811A (zh) * 2015-02-27 2015-07-01 上海臣邦医药科技有限公司 一种糖皮质激素雾化吸入混悬液及其制备方法
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
WO2023136787A1 (en) * 2022-01-17 2023-07-20 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Process for the preparation of a sterile, homogeneous suspension for inhalation by nebulization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235222A (en) 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
JPH0486921A (ja) * 1990-07-31 1992-03-19 Omron Corp 近似推論のための知識ベース形成方法および装置
US5046326A (en) * 1990-10-24 1991-09-10 Thermo King Corporation Transport refrigeration system
IT1243911B (it) * 1990-11-19 1994-06-28 Zambon Spa Composizioni per la terapia mucolitica
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
UY24147A1 (es) * 1995-01-20 1996-02-02 Gruenenthal Chemie Procedimiento y dispositivo para preparar composiciones dispersables por aspersion de aerosoles
US6135628A (en) * 1995-10-13 2000-10-24 Boehringer Ingelheim Pharmceuticals, Inc. Method and apparatus for homogenizing aerosol formulations
IT1286496B1 (it) * 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter

Also Published As

Publication number Publication date
NO20012175D0 (no) 2001-05-02
EP1126823A2 (de) 2001-08-29
EP1832279A3 (de) 2008-03-05
PL347908A1 (en) 2002-04-22
BR9915251A (pt) 2001-10-30
NZ511305A (en) 2003-07-25
DK1832279T3 (en) 2015-10-05
KR100783096B1 (ko) 2007-12-07
TR200101209T2 (tr) 2001-09-21
NO20012175L (no) 2001-07-02
CA2349268A1 (en) 2000-05-11
CZ2007211A3 (cs) 2017-09-27
CA2349268C (en) 2009-03-31
SK285487B6 (sk) 2007-02-01
AU1266600A (en) 2000-05-22
DK1126823T3 (da) 2007-05-21
ES2281197T3 (es) 2007-09-16
PT1126823E (pt) 2007-04-30
BRPI9917701B1 (pt) 2016-07-19
SK5932001A3 (en) 2001-11-06
AU762367B2 (en) 2003-06-26
CZ306939B6 (cs) 2017-09-27
WO2000025746A2 (en) 2000-05-11
SI1126823T1 (sl) 2007-04-30
HU226734B1 (en) 2009-08-28
US6464958B1 (en) 2002-10-15
JP2002528484A (ja) 2002-09-03
PL195908B1 (pl) 2007-11-30
IT1303692B1 (it) 2001-02-23
CZ300650B6 (cs) 2009-07-08
CN1335766A (zh) 2002-02-13
BRPI9915251B8 (pt) 2021-05-25
ZA200103526B (en) 2002-06-03
CA2614633C (en) 2010-12-21
DE69935002D1 (de) 2007-03-15
SK288316B6 (sk) 2015-11-03
EP1832279A2 (de) 2007-09-12
HU230121B1 (hu) 2015-08-28
BRPI9915251B1 (pt) 2015-09-01
DE69935002T2 (de) 2007-07-19
CZ20011541A3 (cs) 2001-09-12
CN1158997C (zh) 2004-07-28
EA003228B1 (ru) 2003-02-27
EP1126823B1 (de) 2007-01-24
CY1107659T1 (el) 2013-04-18
EP1832279B1 (de) 2015-07-01
CA2614633A1 (en) 2000-05-11
HU0700446D0 (en) 2007-08-28
EA200100397A1 (ru) 2001-10-22
WO2000025746A3 (en) 2000-10-26
KR20010075656A (ko) 2001-08-09
ITMI982364A1 (it) 2000-05-03
HUP0104230A2 (hu) 2002-03-28
CY1116943T1 (el) 2017-04-05
HUP0104230A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
DE69935002D1 (de) Verfahren zur herstellung von pharmazeutisch akzeptierbares und steriles beclomethasone dipropionate
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CH680983A5 (de)
JPH11501620A (ja) アデノシン欠乏の治療方法
KR970704422A (ko) 투여용 약제학적 조성물
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
DE69737510D1 (de) Verwendung eines unverkapselten anti-krebs-wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
EP1690539A3 (de) Tiotropiumsalze zur Behandlung von inflammatorischen Erkrankungen
ATE229799T1 (de) Verwendung von phospholipiden zur herstellung eines arzneimittels zur behandlung von asthma
BR0304821A (pt) Processo de preparação de uma suspensão estéril de partìculas de corticosteróide para administração por inalação
AU2003248791A1 (en) Method for preparation of poly-iclc and uses thereof
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
AU4286800A (en) Method for screening drug preparations
DE10159291A1 (de) Verfahren zur Herstellung eines partiellen oder vollständigen Wirkstoffüberzuges auf und in Implantaten und Onplantaten
EP1683514B1 (de) Verfahren zur Herstellung konzentrierter Suspensionen und Kit davon
ATE285784T1 (de) Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
Rice et al. Repair of subglottic stenosis with a free perichondrial graft
Israel et al. 66 Levalbuterol is effective in the prevention of cold air induced bronchospasm and des not induce tachyphylaxis in the degree of bronchoprotection
DE602004004698T2 (de) Verwendung von Stanozolol zur Herstellung von entzündungshemmenden und antidegenerativen Arzneimitteln
ATE191462T1 (de) Im kardiovaskulären system aktive seco-d- steroide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen
Moore et al. 67 Placebo controlled comparative trial of albuterol delivered by a new handheld ultrasonic metered dose solution inhaler (MSI) compared with a standard metered dose inhaler (MDI)
ATE323481T1 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
Levet et al. Inhaled Chemotherapy: Development of Immediate and Controlled-release cisplatin Dry Powders Formulations
GEP20032898B (en) Integrin Receptor Antagonists, Pharmaceutical Composition Containing the Same and Methods for Treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1126823

Country of ref document: EP